mesocarb

Mesocarb

Description:
New class of Dopamine reuptake inhibitor for treating L-DOPA-induced dyskinesias and potentiating anti-Parkinsonian activity

For treating:
CNS conditions, including Parkinson’s dyskninesias and sleep disorders

Current Phase:
Phase 2 ready

KEY HIGHLIGHTS
  • Strong track record of safety...
    Previously marketed outside of the U.S.
  • Over 40 clinical publications
  • Over one million patient-years exposure to date
  • Strong proof of concept in Parkinson's dyskninesias
  • Potential to initiate U.S. registration studies within 24 months

Overview: Mesocarb is currently in development for L-DOPA-induced dyskinesia in Parkinson’s disease (PD-LID). The product has been marketed outside the United States for a variety of CNS conditions. Mesocarb is well characterized in over 40 clinical publications and has over one million patient exposures to date.

DOWNLOAD MORE INFO